Clinical trial
Budesonide / Formoterol in Treatment of Exacerbations of COPD
NCT00239278 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00239278 |
|---|---|
| Title | Budesonide / Formoterol in Treatment of Exacerbations of COPD |
| Official title | Effects of High Dose Inhaled Budesonide+ Formoterol Versus Placebo and Oral Prednisolone on Biomarkers of Airway Inflammation in the Treatment of Exacerbations in Non-hospitalised Patients With Mild to Moderate COPD. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease |
| Intervention type | Drug |
| Interventions | budesonide/formoterol, 2x 200/6 microgram. 4 times daily, prednisolone, 30 mg once daily and placebo |
| Enrollment | 120 |
| Start date | Jan 1, 2001 |
| Completion | Jan 1, 2005 |
| First posted | Oct 17, 2005 |
| Last update posted | Jan 24, 2011 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: